Dnmt3a Polyclonal Antibody

Product Specifications

Background

The tumor organization has the DNA methylation disorder, including and damps cancer gene high methylation DNA with the cell multiplication cycle close related cancer gene low methylation the methyl transferase (Dnmt) participation methylation the formation (is mainly Dnmt3a and Dnmt3b) and the maintenance (is mainly Dnmt1) (isoform CRA_b) (DNA methyltransferase MmuIIIA) (DNA MTase MmuIIIA)

Synonyms

DNA (cytosine 5) methyltransferase 3 alpha; DNA (cytosine 5) methyltransferase 3A; DNA cytosine methyltransferase 3A2; DNA methyltransferase 3a; DNA methyltransferase HsaIIIA; DNA MTase HsaI; DNA MTase HsaIIIA; DNMT 3a; DNMT; Dnmt3a; DNMT3A2; M HsaIIIA; M.HsaIIIA; MCMT; Methyl CpG binding domain protein 3a.

Gene ID

1788

Swiss Prot

Q9Y6K1

Cellular Locus

Cytoplasm, Nucleus

Host

Rabbit

Cross Reactivity

Human, Mouse, Rat

Immunogen

51-150/912

Target

Dnmt3a

Clonality

Polyclonal

Isotype

IgG

Conjugation

Unconjugated

Source

KLH conjugated synthetic peptide derived from human DNMT-3 alpha

Applications

WB, ELISA, FCM, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Concentration

1µg/µl

Dilution

WB (1:300-5000), ELISA (1:500-1000), FCM (1:20-100), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)